Chimeric antigen receptor T cells for cancer immunotherapy

Journal of Clinical Oncology

Volumn 33, Issue 15, 2015, Pages 1703-1706

  Curran, Kevin J ^a   Brentjens, Renier J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE IX; CARCINOEMBRYONIC ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERLEUKIN 10; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN;

ANTIGEN BINDING; ARTICLE; CANCER IMMUNOTHERAPY; DRUG CYTOTOXICITY; HUMAN; IMMUNORECEPTOR TYROSINE BASED ACTIVATION MOTIF; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; BONE NEOPLASMS; FEMALE; IMMUNOLOGY; IMMUNOTHERAPY; MALE; METABOLISM; PROCEDURES; SARCOMA;

BONE NEOPLASMS; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; RECEPTOR, ERBB-2; SARCOMA; T-LYMPHOCYTES;

EID: 84933526394     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.60.3449     Document Type: Article

References (27)

1. Curran KJ, Pegram HJ, Brentjens RJ: Chimeric antigen receptors for T cell immunotherapy: Current understanding and future directions. J Gene Med 14:405-415, 2012
2. Davila ML, Riviere I, Wang X, et al: Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6:224ra25, 2014
3. Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al: T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial. Lancet 385:517-528, 2015
4. Maude SL, Frey N, Shaw PA, et al: Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371:1507-1517, 2014
5. Kochenderfer JN, Dudley ME, Kassim SH, et al: Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 33:540-549, 2015
6. Lamers CH, Sleijfer S, Vulto AG, et al: Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: First clinical experience. J Clin Oncol 24:e20-e22, 2006
7. Kershaw MH, Westwood JA, Parker LL, et al: A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 12:6106-6115, 2006
8. Park JR, Digiusto DL, Slovak M, et al: Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 15:825-833, 2007
9. Parkhurst MR, Yang JC, Langan RC, et al: T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 19:620-626, 2011
10. Louis CU, Savoldo B, Dotti G, et al: Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118:6050-6056, 2011
11. Ahmed N, Brawley V, Hedge M, et al: Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of osteosarcoma. J Clin Oncol 33:1688-1696, 2015
12. Morgan RA, Yang JC, Kitano M, et al: Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18:843-851, 2010
13. Seidman A, Hudis C, Pierri MK, et al: Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20:1215-1221, 2002
14. Lamers CH, Sleijfer S, van Steenbergen S, et al: Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: Clinical evaluation and management of on-target toxicity. Mol Ther 21:904-912, 2013
15. Kloss CC, Condomines M, Cartellieri M, et al: Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 31:71-75, 2013
16. Savoldo B, Ramos CA, Liu E, et al: CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 121:1822-1826, 2011
17. Lamers CH, Willemsen R, van Elzakker P, et al: Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 117:72-82, 2011
18. Dao T, Yan S, Veomett N, et al: Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Sci Transl Med 5:176ra33, 2013
19. Brentjens RJ, Rivière I, Park JH, et al: Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118:4817-4828, 2011
20. Berger C, Jensen MC, Lansdorp PM, et al: Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 118:294-305, 2008
21. Di Stasi A, Tey SK, Dotti G, et al: Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365:1673-1683, 2011
22. Wang X, Chang WC, Wong CW, et al: A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118:1255-1263, 2011
23. Vesely MD, Kershaw MH, Schreiber RD, et al: Natural innate and adaptive immunity to cancer. Annu Rev Immunol 29:235-271, 2011
24. Pegram HJ, Lee JC, Hayman EG, et al: Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119:4133-4141, 2012
25. Pegram HJ, Park JH, Brentjens RJ: CD28z CARs and armored CARs. Cancer J 20:127-133, 2014
26. Hoyos V, Savoldo B, Quintarelli C, et al: Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 24:1160-1170, 2010
27. Dotti G, Gottschalk S, Savoldo B, et al: Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev 257:107-126, 2014